Drug intelligence / Profile preview

PTT-004

Development stage: Preclinical
Lead developer: Pyrotech Therapeutics

Overview

PTT-004 is an investigational drug candidate being developed by Pyrotech Therapeutics for the treatment of inflammatory bowel disease (IBD). As of early 2024, the candidate is in the preclinical stage of development. While the specific molecular target and modality have not been publicly disclosed in the company's primary pipeline documentation, Pyrotech Therapeutics focuses on modulating inflammatory pathways, often associated with innate immunity and cell death mechanisms. PTT-004 is part of a broader portfolio aimed at addressing autoimmune and anti-inflammatory conditions.

Beyond the preview

Go deeper on PTT-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTT-004.

Explore the full profile